Israel vs Trinidad and Tobago: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Israel
0.1%
in 2024
Trinidad and Tobago
0.1%
in 2024
Israel rank
134th
Trinidad and Tobago rank
134th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Israel
- Trinidad and Tobago
How they compare
Israel currently reports 0.1% against 0.1% in Trinidad and Tobago, a difference of 0.0%.
The two have swapped places 3 times across 10 shared years of data; in 2015 it was Israel ahead.
Israel ranks 134th and Trinidad and Tobago ranks 134th of 246 countries.
Israel has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Israel | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.2% | 0.1% | Israel |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Israel or Trinidad and Tobago?
- Israel, at 0.1% against 0.1% in Trinidad and Tobago as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Israel and Trinidad and Tobago?
- 0.0%, with Israel ahead.
- How many years of comparable data are there for Israel and Trinidad and Tobago?
- 10 years are reported by both, from 2015 to 2024.
- How do Israel and Trinidad and Tobago rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Israel ranks 134th and Trinidad and Tobago ranks 134th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.